|Articles|December 6, 2011

C. diff Infection Prolongs Hospital Length of Stay

The effect of hospital-acquired infection with Clostridium difficile on length of stay in hospital is not yet fully understood. Alan J. Forster, of the Clinical Epidemiology Program at Ottawa Hospital Research Institute, and colleagues, determined the independent impact of hospital-acquired infection with C. difficile on length of stay in hospital.

The researchers conducted a retrospective observational cohort study of admissions to hospital between July 1, 2002, and Mar. 31, 2009, at a single academic hospital. They measured the association between infection with hospital-acquired C. difficile and time to discharge from hospital using Kaplan-Meier methods and a Cox multivariable proportional hazards regression model. They controlled for baseline risk of death and accounted for C. difficile as a time-varying effect.

Hospital-acquired infection with C. difficile was identified in 1,393 of 136 877 admissions to hospital (overall risk 1.02%, 95% confidence interval [CI] 0.97%1.06%). The crude median length of stay in hospital was greater for patients with hospital-acquired C. difficile (34 d) than for those without C. difficile (8 d). Survival analysis showed that hospital-acquired infection with C. difficile increased the median length of stay in hospital by six days. In adjusted analyses, hospital-acquired C. difficile was significantly associated with time to discharge, modified by baseline risk of death and time to acquisition of C. difficile. The hazard ratio for discharge by day 7 among patients with hospital-acquired C. difficile was 0.55 (95% CI 0.390.70) for patients in the lowest decile of baseline risk of death and 0.45 (95% CI 0.320.58) for those in the highest decile; for discharge by day 28, the corresponding hazard ratios were 0.74 (95% CI 0.600.87) and 0.61 (95% CI 0.530.68).

The researchers concluded that hospital-acquired infection with C. difficile significantly prolonged length of stay in hospital independent of baseline risk of death. Their research was published in the Canadian Medical Association Journal.

Reference: Forster AJ, Taljaard M, Oake N, Wilson K, Roth V and van Walrave C. The effect of hospital-acquired infection with Clostridium difficile on length of stay in hospital. CMAJ Dec. 5, 2011. doi: 10.1503/cmaj.110543

Stay prepared and protected with the Infection Control Today newsletter, delivering essential updates, best practices, and expert insights for infection prevention professionals.

Related to this article

Weekly Rounds With Infection Control Today

October 30th, 2026

ICT Weekly Rounds: Ebola Execution Gaps, a Midge-Borne Virus Jumps to Humans, and IDWeek Findings

This week in infection prevention: Kenya’s Bundibugyo virus response shows why execution, not just planning, determines outcomes, and France reported the first known human Shamonda virus infection. Our roundup also covers brucellosis, blood donor screening, and long-acting HIV antibody findings from IDWeek 2026.

October 23rd, 2026

IDWeek 2026: ICU Study Finds Lower Glove Bioburden With PostCare Alcohol Application

An ICU study found that alcohol-based hand rub applied after patient care reduced glove bioburden, while staff raised feasibility concerns. Researchers stress that the practice does not replace glove changes or hand hygiene.

Image of Pathogens flying (Adobe Stock weerasak)

October 6th, 2026

How 3 Decades of SHEA Presidents Shaped the Science and Soul of Infection Prevention

Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.

November 11th, 2026

Ebola Response in the DRC: Contact Tracing Gaps and the Role of Community Trust

An infection preventionist examines the DRC’s Ebola response through contact tracing and community engagement, explaining why daily follow-up, timely investigations, and trust reveal challenges that cumulative case counts alone cannot capture.

Five columns of coins on a wooden tabletop with a world map as a background (Adobe Stock 189818391 by Paulo)

November 11th, 2026

Vaccine Development in LMICs: Financing, Clinical Trial Capacity, and Equitable Access

Four vaccine experts discuss how sustained financing, local research leadership, and community trust can strengthen vaccine development in low- and middle-income countries (LMICs), drawing on practical insights from India and Bangladesh.

Rows of Covid-19 vaccine bottles in a row on a reflective surface 3d render (Adobe Stock 443454986 by Studio-FI)

November 10th, 2026

From Stockpile to Patient: Preparing Vaccine Delivery Before an Outbreak

GeoVax CEO David Dodd discusses how vaccine storage requirements, supplier diversification, and regional manufacturing shape outbreak preparedness, with considerations for infection preventionists and health systems preparing to receive and administer doses.

Sterile Processing Perspectives With Marjorie Wall, EDBA, MLOS, CRCST, CIS, CHL, CSSBB

November 10th, 2026

The Next Generation of SPD Leadership: From the Basement to the Boardroom

Part 4 of 4: Why better planning for surgical growth, operational performance, and patient safety requires sterile processing expertise early in the decision-making process.

Fungi Trichophyton mentagrophytes, 3D illustration (Adobe Stock 507127362 by Dr_Microbe)

November 9th, 2026

TMVII Sexually Transmitted Ringworm: Symptoms, Diagnosis, Treatment, and Prevention

An emerging cause of sexually transmitted ringworm, TMVII can resemble other skin conditions and require prolonged treatment. Learn what clinicians and infection preventionists should know about recognition, specialized testing, and patient counseling.